Yet, there is limiting evidence for low levels of NPs in the prediction of clinical outcomes among HF patients treated with the four-pillar guideline-recommended combination, which includes the renin–angiotensin–aldosterone system mainly ARNI and MCA, beta-blocker, and SGLT2 inhibitor [41]. This evidence concerns the gene SLC5A2 and hydrops fetalis.